ES

Elliott Sigal

North America, New Jersey, United States, Princeton

Description

Elliott Sigal, M.D., Ph.D. joined NEA as a Venture Partner and Senior Advisor in 2014. He is a former Executive Vice President and Director ...

Investor Profile

Elliott Sigal has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 2 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Health Care, Medical.

Stage Focus

  • Series B (50%)
  • Series A (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Life Science
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Elliott Sigal frequently co-invest with?

Amgen Ventures
North America, California, United States, San Francisco
Co-Investments: 1
Pfizer Venture Investments
North America, New York, United States, New York
Co-Investments: 1
New Enterprise Associates
North America, California, United States, Menlo Park
Co-Investments: 2
Novartis Institutes for Biomedical Research
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 1
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 1
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Lilly Ventures
North America, Indiana, United States, Indianapolis
Co-Investments: 1

What are some of recent deals done by Elliott Sigal?

Mersana Therapeutics

Cambridge, Massachusetts, United States

Mersana Therapeutics develops a biodegradable polymer platform Fleximer® which creates new and better medicines.

BiotechnologyHealth CareMedicalTherapeutics
Series BMar 2, 2015
Amount Raised: $35,000,000
Surface Oncology

Cambridge, Massachusetts, United States

Surface Oncology develops next-generation cancer immunotherapy treatments based on proprietary discoveries.

BiotechnologyHealth CareLife ScienceOncology
Series AJan 8, 2015
Amount Raised: $35,000,000